3. The polypeptide of claim 2, wherein the variant is the translation of a single nucleotide polymorphism.

4. The polypeptide of claim 1 that is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.

29. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

32. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.

44. A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising SEQ ID NO: 22.

45. The method of claim 44 wherein the cell is a bacterial cell.

46. The method of claim 44 wherein the cell is an insect cell.

47. The method of claim 44 wherein the cell is a yeast cell.

48. The method of claim 44 wherein the cell is a mammalian cell.

REMARKS

In response to the Office Action dated June 21, 2002, Applicants elect the invention of Group I (Claims 1-4, 29 and 32), drawn to isolated polypeptides, with traverse. In addition, Applicants also elect the invention of SEQ ID NO: 22. Claims 1-4, 29, 32 and 44-48 are currently pending. Cancel claims 5-28, 30-31 and 33-43 without prejudice or disclaimer. Claims 1 and 2 have been amended and new claims 44-48 have been added. Support for the amendment